VANCOUVER, Oct. 3 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX)
announced today that the Company will be presenting at two upcoming forums.
Presentations will include highlights of the recent acquisition of PRX-321, a
phase two program for the treatment of primary brain cancer, as well as
updates on the PRX-302 development programs for prostate cancer and benign
prostatic hyperplasia.
